Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05846659 · ClinicalTrials.gov registry record · Phase 2
Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies
A Phase 2 study, sponsored by ImmuneSensor Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT05846659: Clinical Trial Phase 2 study, sponsored by ImmuneSensor Therapeutics.
NCT05846659 is a Phase 2 study that was terminated before completion, run by ImmuneSensor Therapeutics. The registered enrollment target is 16 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05846659, a Phase 2 study, was terminated before completion, sponsored by ImmuneSensor Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
Phase 2, open-label, multicenter, randomized study comparing the safety and efficacy of personalized ultra-fractionated stereotactic adaptive radiotherapy (PULSAR) combined with immune checkpoint inhibitor (ICI) immunotherapy (PULSAR-ICI) + IMSA101 and PULSAR-ICI alone in patients with oligoprogressive solid tumor malignancies after prior anti-cancer therapy.
Primary Outcome
Progression-free rate at 12 months
Interventions
- DRUG IMSA101
- DRUG Immune checkpoint inhibitor
- RADIATION PULSAR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2023-07-07 |
| Est. Completion | 2024-11-20 |
| Phase | Phase 2 |
Why NCT05846659 stopped before completion
NCT05846659 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 3 interventions - of which IMSA101 is the first listed.
NCT05846659 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05846659 about?
NCT05846659 is a clinical study titled "Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies". Phase 2, open-label, multicenter, randomized study comparing the safety and efficacy of personalized ultra-fractionated stereotactic adaptive radiotherapy (PULSAR) combined with immune checkpoint inhibitor (ICI) immunotherapy (PULSAR-ICI) + IMSA101 and PULSAR-ICI alone in patients with oligoprogress...
What is the current status of trial NCT05846659?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2023-07-07. Estimated completion is 2024-11-20.
What interventions are being tested in trial NCT05846659?
The interventions under investigation include: IMSA101 (DRUG), Immune checkpoint inhibitor (DRUG), PULSAR (RADIATION).
Who is sponsoring clinical trial NCT05846659?
This trial is sponsored by ImmuneSensor Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05846659's enrollment target sits among peer trials
16 1908th of 2000 higher than 82 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI